Trial Profile
A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 31 Jan 2021 Results (Data cut off 25 Jan 2020, median follow up duration 19.3 months) assessing OS and PFS2 (time to second progression) based on long-term follow-up, presented at the 2020 World Conference on Lung Cancer.
- 07 Jun 2020 Status changed from recruiting to completed.
- 10 Sep 2019 Interim analysis on efficacy and safety of camrelizumab plus carboplatin/pemetrexed as 1st line treatment in Chinese advanced/metastatic non-squamous NSCLC patients presented at the 20th World Conference on Lung Cancer